Navigation Links
Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
Date:5/14/2008

PITTSBURGH, May 14 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) today announced that Mylan Pharmaceuticals Inc. has launched Paroxetine Hydrochloride (HCl) Extended-release (ER) Tablets, the generic version of GlaxoSmithKline's (GSK) Paxil CR(R). As the first company to successfully file an abbreviated new drug application (ANDA) containing a paragraph IV certification for the 12.5 mg and 25 mg tablets, Mylan has earned 180 days of marketing exclusivity for these two strengths. Reflecting a supply and distribution agreement with GSK, Mylan also has the right to market the 37.5 mg strength. Mylan is not aware of any other ANDA filers with paragraph IV certifications for this product.

"As another first-to-file opportunity, Paroxetine HCl ER reflects Mylan's continued dynamic speed-to-market capabilities," says Robert J. Coury, Mylan's vice chairman and CEO. "Because this product also belongs in the 'difficult- to-manufacture' category, it is yet another example of our historically strong R&D process, through which we're able to deliver affordable versions of important complex therapies. Our settlement with GSK is consistent with our commitment to monetize opportunities when it benefits both patients and our shareholders."

Paroxetine HCl ER Tablets had U.S. sales of approximately $301 million for the 12 months ending March 31, 2008, for all three strengths.

In October 2007, Mylan announced the settlement of patent litigation involving Paroxetine HCl ER. At that time, Mylan stated that the settlement would provide the company with patent licenses and the right to market all three strengths beginning no later than Oct. 1, 2008. As part of the settlement agreement, which remains confidential, Mylan has been provided with the patent licenses needed to distribute the product immediately.

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
4. Mylan Announces Final FDA Approval for Trandolapril Tablets
5. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
6. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
7. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
8. Mylan Revises Timing of Its Financial Results Conference Call for the Quarter and Nine Months Ended Dec. 31, 2007, to 5 p.m. ET
9. Mylan Confirms Its Matrix Design Fentanyl Patch Is Not Included In the Widespread Recall Announced February 12th
10. Mylan Restores Availability of Generic Levothyroxine in Florida
11. Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators are ... saves lives. However, if one isn’t accessible in certain locations, the risk of ... I came up with this idea," said an inventor from Ridgecrest, Calif. , ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, ... Educational Leadership and Administration at St. Thomas University in Miami, Florida, was selected ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... emergency rooms is celebrating the one year anniversary of its Houston-Fallbrook facility. ... said Dr. Otinwa, Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It ...
(Date:9/22/2017)... Diego, CA (PRWEB) , ... September 22, 2017 ... ... offer groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, ... Smart Mart has stated to offer wearable, and customers can find clothing at ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , ... wrong, run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... STOCKHOLM , Sept. 7, 2017 NuvoAir ... Air Smart Spirometer, announced today a partnership with Novartis Pharma ... partnership solidifies NuvoAir,s position as the leading mobile spirometry platform ... respiratory patients. ... spirometry test ...
(Date:9/6/2017)... ORANGEBURG, N.Y. , Sept. 6, 2017   PDI ... today announced it will host an educational session focused ... line-associated bloodstream infection (CLABSI) prevention at the 2017 Annual ... meeting, which will take place at the ... Arizona from Sept. 16-19, will also feature ...
(Date:9/5/2017)... 5, 2017  Getinge, a leading global provider ... charitable donation program -- "Color for the Kids!" ... defect research by The Children,s Heart Foundation. Pediatric ... public are encouraged to download a coloring picture ... artwork to the gallery on the website. For ...
Breaking Medicine Technology: